Cannabis
Rescheduling

Cannabis rescheduling refers to the process of moving cannabis from Schedule I to Schedule III under the US Controlled Substances Act. Schedule I is reserved for substances the federal government considers to have no accepted medical use and a high potential for abuse — a category that includes heroin and LSD. Schedule III covers substances with accepted medical uses and a moderate-to-low potential for dependence.

The reclassification would not legalise cannabis federally, but it would meaningfully change how it is regulated, taxed and researched.

Yes, but only partly. Medical cannabis, that is cannabis which falls under state medical licence or is FDA approved, has now been moved to Schedule III, and is suitable for 280E tax relief. Any cannabis that is not covered by a state medical license or an FDA approval remains a Schedule I controlled substance. In a nutshell, this means that adult-use cannabis has not been moved to Schedule III. As such, recreational operators, including those in the 24 states with adult-use markets, cannot immediately claim Schedule III status or 280E relief for their non-medical operations. Unlicensed bulk marijuana, recreational cannabis, synthetic THC and cannabis extracts outside the medical licensing system are all explicitly excluded from reclassification.

For the most up-to-date status, see The US Officially Reschedules Cannabis — Partly and The Fight Is Far From Over.

The most immediate benefit of rescheduling is is the end of IRC Section 280E, the tax provision that prevents cannabis operators from deducting ordinary business expenses. Removing 280E would materially improve cash flow for nearly every plant-touching operator, particularly multi-state operators (MSOs) carrying heavy effective tax burdens. Notably, many operators have already begun pre-emptively withholding 280E tax payments and may have to pay millions in back taxes. The longer-term benefits could be more significant. Primarily, the downgrading of cannabis should remove lots of bureaucratic barriers to carrying out clinical cannabis research. Rescheduling would also make cannabis research a more attractive investment. It would not impact cannabis firms' access to banking, but would reduce the risk for institutional investors to take a position in the sector.

It could also remove barriers for companies to list on public markets, and enable international trade of medical cannabis with other countries. See our reporting on the MSO tax exposure.

No. Rescheduling moves cannabis to a less stringent category within the Controlled Substances Act, it does not legalise cannabis at the federal level. Recreational cannabis would remain federally illegal, and existing state markets would continue to operate within their own legal frameworks. Federal legalisation would require an act of Congress, not an administrative rescheduling.

The DEA's rulemaking process has been delayed by witness disputes, lawsuits, allegations of agency bias, leadership changes, and political pressure from Capitol Hill. Multiple participants have challenged the DEA's conduct — and the agency itself has navigated subpoena requests, hearing reschedules and a change in administrator. See our DEA & Legal Process cluster for the full chronology.

Cannabis equities have moved sharply on every major rescheduling signal — rallying on positive announcements and selling off on delays. The pattern is now well-established enough that some analysts characterise rescheduling-driven moves as their own discrete trading regime.

For ongoing market reaction, see our Cannabis Stocks Hub.

Yes — and political opposition has explicitly sought to do so. Republican lawmakers have introduced legislation to block 280E relief even if cannabis is rescheduled, and US spending bills have included provisions targeting funding for the rescheduling process. The administrative pathway is also subject to legal challenge. Anyone modelling the impact of rescheduling needs to account for the possibility of partial rollback, though now meaningful progress has been made, this offers some form of security.

US rescheduling has an outsized influence on international markets. Given the relatively small size of the international cannabis industry, especially on public markets, any significant movement in the largest cannabis market on earth has implications across the globe. Rescheduling also brings the US medical cannabis regime more closely in line with Single Convention regulations, meaning that international cannabis trade with the US could be possible for the first time. European operators, in particular, are now examining what opportunities this presents, with Cannabis Europa London 2026 expected to be the first major industry gathering to formally take stock of the shift. See our preview. See our preview.